LEADER 03913nam  2200889z- 450 
001 9910404087203321
005 20210211
010   $a3-03928-041-4
035   $a(CKB)4100000011302266
035   $a(oapen)https://directory.doabooks.org/handle/20.500.12854/53236
035   $a(oapen)doab53236
035   $a(EXLCZ)994100000011302266
100   $a20202102d2020      |y         0
101 0 $aeng
135   $aurmn|---annan
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 00$aMetabolomics in Neurodegenerative Disease
210   $cMDPI - Multidisciplinary Digital Publishing Institute$d2020
215   $a1 online resource (184 p.)
311 08$a3-03928-040-6 
330   $aThe range of human neurodegenerative diseases continues to pose significant unmet medical needs for societies around the world. The progressive and terminal nature of these conditions places a considerable personal burden on the individual affected but also on public health systems and health services. Tens of millions of people are indiscriminately affected by various dementias, which are rising at an alarming rate. There are no cures for many conditions, and it is clear that treatments applied as early as possible could greatly improve outcomes for patients. Therefore, new disease classification and diagnostic tools should be a key priority. Metabolomics represents a relatively new field of analytical science, which can be extremely useful in the early diagnosis of disease. The relatively unique feature of metabolites is that they sit at the intersection between the genetic background of an organism and its environment. Because many neurodegenerative diseases are not genetically inherited (instead having a range of known genetic risk factors and also a large number of unknown environmental triggers) the field of metabolomics offers great promise for the discovery of new, biologically, and clinically relevant biomarkers for neurodegenerative disorders. It is already bringing forward new knowledge in terms of the mechanisms of neurodegenerative disease.
606   $aBiology, life sciences$2bicssc
610   $a?-synuclein aggregates
610   $a13C-labeled succinate
610   $a1H NMR
610   $a6-OHDA
610   $aage-related macular degeneration
610   $aAlzheimer's disease
610   $abile acids
610   $abiomarkers
610   $aC. elegans
610   $acerebral ischemia
610   $acerebral palsy
610   $adementia with Lewy bodies
610   $adirect mass spectrometry
610   $adrusen
610   $aendothelin-1
610   $aenergy metabolism
610   $aexcitotoxicity
610   $afatty acid
610   $afatty acid metabolism
610   $aGC-MS
610   $aglutamic acid
610   $aimaging mass spectrometry
610   $aLC-MS
610   $alipidomics
610   $amalonate
610   $amass spectrometry
610   $ametabolic pathways
610   $ametabolism
610   $ametabolomics
610   $amicro-dialysis
610   $amidbrain
610   $amitochondrial dysfunction
610   $amyo-inositol
610   $an/a
610   $anatural product
610   $aneurodegeneration
610   $aParkinson's disease
610   $aParkinson's disease dementia
610   $apathogenesis
610   $aplasma
610   $aprodromal Parkinson's disease
610   $areperfusion
610   $aretinal pigment epithelium
610   $aStreptomyces venezuelae
610   $asubacute mild traumatic brain injury
610   $atargeted mass spectrometry
610   $atricarboxylic acid cycle
615  7$aBiology, life sciences
700   $aGreen$b Brian$4auth$0732791
906   $aBOOK
912   $a9910404087203321
996   $aMetabolomics in Neurodegenerative Disease$93032111
997   $aUNINA